JP2012516897A - シュードモナス・エルギノーサ（ＰｓｅｕｄｏｍｏｎａｓＡｅｒｕｇｉｎｏｓａ）感染の治療のための抗生物質と抗体療法との組み合わせ - Google Patents

シュードモナス・エルギノーサ（ＰｓｅｕｄｏｍｏｎａｓＡｅｒｕｇｉｎｏｓａ）感染の治療のための抗生物質と抗体療法との組み合わせ Download PDF

Info

Publication number
JP2012516897A
JP2012516897A JP2011549261A JP2011549261A JP2012516897A JP 2012516897 A JP2012516897 A JP 2012516897A JP 2011549261 A JP2011549261 A JP 2011549261A JP 2011549261 A JP2011549261 A JP 2011549261A JP 2012516897 A JP2012516897 A JP 2012516897A
Authority
JP
Japan
Prior art keywords
region
segment
sequence
antibody
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011549261A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012516897A5 (enExample
Inventor
マーク ベア
クリストファー アール． ベビントン
ジェフリー ティー． ヤラントン
スーザン リンチ
ユアンリン ソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of JP2012516897A publication Critical patent/JP2012516897A/ja
Publication of JP2012516897A5 publication Critical patent/JP2012516897A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011549261A 2009-02-04 2010-02-04 シュードモナス・エルギノーサ（ＰｓｅｕｄｏｍｏｎａｓＡｅｒｕｇｉｎｏｓａ）感染の治療のための抗生物質と抗体療法との組み合わせ Pending JP2012516897A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14995709P 2009-02-04 2009-02-04
US61/149,957 2009-02-04
PCT/US2010/023214 WO2010091189A1 (en) 2009-02-04 2010-02-04 Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection

Publications (2)

Publication Number Publication Date
JP2012516897A true JP2012516897A (ja) 2012-07-26
JP2012516897A5 JP2012516897A5 (enExample) 2013-03-21

Family

ID=42133763

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011549261A Pending JP2012516897A (ja) 2009-02-04 2010-02-04 シュードモナス・エルギノーサ（ＰｓｅｕｄｏｍｏｎａｓＡｅｒｕｇｉｎｏｓａ）感染の治療のための抗生物質と抗体療法との組み合わせ

Country Status (5)

Country Link
US (1) US20100272736A1 (enExample)
EP (1) EP2393515A1 (enExample)
JP (1) JP2012516897A (enExample)
CA (1) CA2751433A1 (enExample)
WO (1) WO2010091189A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013515079A (ja) 2009-12-22 2013-05-02 カロバイオス ファーマシューティカルズ インコーポレイティッド 低レベルの病原性シュードモナス・エルギノーサ（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）感染症を有する患者のスタフィロコッカス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）感染症を治療する方法
KR102111171B1 (ko) 2011-06-10 2020-05-14 메디뮨 엘엘씨 항슈도모나스 ｐｓｌ 결합 분자 및 그의 용도
SMT202000542T1 (it) * 2011-11-07 2020-11-10 Medimmune Ltd Terapie di combinazione utilizzando molecole di legame anti-psl e pcrv di pseudomonas
CN114072145B (zh) * 2020-06-01 2024-06-11 北京三诺佳邑生物技术有限责任公司 特异性识别假单胞菌pcrv的抗体及其用途
FR3114970B1 (fr) 2020-10-08 2023-06-30 Univ Tours Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires
WO2024261584A1 (en) * 2023-06-17 2024-12-26 Abgenics Lifesciences Private Limited A composition effective against beta-lactam antibiotic-resistant pseudomonas aeruginosa

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62187417A (ja) * 1985-12-10 1987-08-15 ジエネテイツク　システムズ　コ−ポレ−シヨン 緑膿菌血清型に対する交さ反応性かつ交さ防御性単クロ−ン性抗体
JPS63500035A (ja) * 1985-06-06 1988-01-07 ジエネテイツク　システムズ　コ−ポレイシヨン プソイドモナス　アエルギノサ　外毒素ａに対する保護用ヒトモノクロ−ナル抗体
JPS63102697A (ja) * 1986-07-03 1988-05-07 ジエネテイツク　システムズ　コ−ポレ−シヨン シュ−ドモナスアエルギノ−ザ鞭毛に対するモノクロ−ナル抗体
JP2005500250A (ja) * 2001-01-26 2005-01-06 エムシーダブリユー リサーチ フオンデーシヨン インコーポレーテツド シュードモナスｖ抗原を用いる免疫化のための方法および組成物
WO2008030988A2 (en) * 2006-09-06 2008-03-13 The Regents Of The University Of California Selectively targeted antimicrobial peptides and the use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
AU3580800A (en) 1998-11-25 2000-06-26 Mcw Research Foundation, Inc. Method of and compositions for immunization with the (pseudomonas) v antigen
EP1761561B1 (en) 2004-01-20 2015-08-26 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
AU2005306502B2 (en) 2004-11-16 2012-11-15 Humanigen, Inc. Immunoglobulin variable region cassette exchange
US8211648B2 (en) 2005-07-22 2012-07-03 Kalobios Pharmaceuticals, Inc. Secretion of antibodies without signal peptides from bacteria
EA201000903A1 (ru) * 2007-11-30 2011-02-28 Калобиос Фармасьютикалс, Инк. Антитела к pcrv-антигену pseudomonas aeruginosa

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63500035A (ja) * 1985-06-06 1988-01-07 ジエネテイツク　システムズ　コ−ポレイシヨン プソイドモナス　アエルギノサ　外毒素ａに対する保護用ヒトモノクロ−ナル抗体
JPS62187417A (ja) * 1985-12-10 1987-08-15 ジエネテイツク　システムズ　コ−ポレ−シヨン 緑膿菌血清型に対する交さ反応性かつ交さ防御性単クロ−ン性抗体
JPS63102697A (ja) * 1986-07-03 1988-05-07 ジエネテイツク　システムズ　コ−ポレ−シヨン シュ−ドモナスアエルギノ−ザ鞭毛に対するモノクロ−ナル抗体
JP2005500250A (ja) * 2001-01-26 2005-01-06 エムシーダブリユー リサーチ フオンデーシヨン インコーポレーテツド シュードモナスｖ抗原を用いる免疫化のための方法および組成物
WO2008030988A2 (en) * 2006-09-06 2008-03-13 The Regents Of The University Of California Selectively targeted antimicrobial peptides and the use thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN5012007144; ＦＡＵＲＥ　ＫＡＲＩＮＥ: 'ＥＦＦＥＣＴＳ　ＯＦ　ＭＯＮＯＣＬＯＮＡＬ　ＡＮＴＩ-ＰＣＲＶ　ＡＮＴＩＢＯＤＹ　ＯＮ　ＰＳＥＵＤＯＭＯＮＡＳ　ＡＥＲＵＧＩＮＯＳＡ-ＩＮＤＵＣＥＤ　以下備考' ＪＯＵＲＮＡＬ　ＯＦ　ＩＭＭＵＮＥ　ＢＡＳＥＤ　ＴＨＥＲＡＰＩＥＳ　ＡＮＤ　ＶＡＣＣＩＮＥＳ Ｖ１　Ｎ１, 20030813, Ｐ２, ＢＩＯＭＥＤ　ＣＥＮＴＲＡＬ　ＬＴＤ． *
JPN5012007145; ＮＥＥＬＹ　Ａ　Ｎ: 'ＰＡＳＳＩＶＥ　ＡＮＴＩ-ＰＣＲＶ　ＴＲＥＡＴＭＥＮＴ　ＰＲＯＴＥＣＴＳ　ＢＵＲＮＥＤ　ＭＩＣＥ　ＡＧＡＩＮＳＴ　ＰＳＥＵＤＯＭＯＮＡＳ　ＡＥＲＵＧＩＮＯＳＡ　ＣＨＡＬＬＥＮＧＥ' ＢＵＲＮＳ Ｖ３１　Ｎ２, 20050301, Ｐ１５３-１５８, ＢＵＴＴＥＲＷＯＲＴＨ　ＨＥＩＮＥＭＡＮＮ *
JPN5012007146; ＦＲＡＮＫ　Ｄ　Ｗ: 'ＧＥＮＥＲＡＴＩＯＮ　ＡＮＤ　ＣＨＡＲＡＣＴＥＲＩＺＡＴＩＯＮ　ＯＦ　Ａ　ＰＲＯＴＥＣＴＩＶＥ　ＭＯＮＯＣＬＯＮＡＬ　ＡＮＴＩＢＯＤＹ　ＴＯ　ＰＳＥＵＤＯＭＯＮＡＳ　ＡＥＲＵＧＩＮＯＳＡ　ＰＣＲＶ' ＪＯＵＲＮＡＬ　ＯＦ　ＩＮＦＥＣＴＩＯＵＳ　ＤＩＳＥＡＳＥＳ Ｖ１８６　Ｎ１, 20020701, Ｐ６４-７３, ＵＮＩＶＥＲＳＩＴＹ　ＯＦ　ＣＨＩＣＡＧＯ　ＰＲＥＳＳ *
JPN5012007147; ＢＡＥＲ　ＭＡＲＫ: 'ＡＮ　ＥＮＧＩＮＥＥＲＥＤ　ＨＵＭＡＮ　ＡＮＴＩＢＯＤＹ　ＦＡＢ　ＦＲＡＧＭＥＮＴ　ＳＰＥＣＩＦＩＣ　ＦＯＲ　ＰＳＥＵＤＯＭＯＮＡＳ　ＡＥＲＵＧＩＮＯＳＡ　ＰＣＲＶ　以下備考' ＩＮＦＥＣＴＩＯＮ　ＡＮＤ　ＩＭＭＵＮＩＴＹ Ｖ７７　Ｎ３, 20081222, Ｐ１０８３-１０９０ *
JPN5012007148; ＬＹＮＣＨ　Ｓ　Ｖ: 'ＮＯＶＥＬ　ＳＴＲＡＴＥＧＩＥＳ　ＴＯ　ＣＯＭＢＡＴ　ＢＡＣＴＥＲＩＡＬ　ＶＩＲＵＬＥＮＣＥ' ＣＵＲＲＥＮＴ　ＯＰＩＮＩＯＮ　ＩＮ　ＣＲＩＴＩＣＡＬ　ＣＡＲＥ Ｖ１４　Ｎ５, 200810, Ｐ５９３-５９９ *
JPN6015008426; 日本化学療法学会雑誌 Ｖｏｌ．　５３，Ｎｏ．　８, 2005, ｐ．　４７６-４８２ *
JPN6015008429; Ｔｈｅ　Ｊａｐａｎｅｓｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ａｎｔｉｂｉｏｔｉｃｓ Ｖｏｌ．　５９，Ｎｏ．　１, 2006, ｐ．　１１-２０ *
JPN6015008431; 感染症学雑誌 Ｖｏｌ．　８２，Ｎｏ．　５, 2008, ｐ．　４６６-４７０ *

Also Published As

Publication number Publication date
EP2393515A1 (en) 2011-12-14
US20100272736A1 (en) 2010-10-28
CA2751433A1 (en) 2010-08-12
WO2010091189A1 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
US12428473B2 (en) Combination therapies using anti-pseudomonas PSL and PCRV binding molecules
JP5781765B2 (ja) シュードモナス・エルギノーサ（ＰｓｅｕｄｏｍｏｎａｓＡｅｒｕｇｉｎｏｓａ）のＰｃｒＶ抗原に対する抗体
JP2011505381A5 (enExample)
US8653242B2 (en) Therapeutic antibodies against flagellated Pseudomonas aeruginosa
US8642039B2 (en) Method of treating a staphylococcus infection in a patient having a low-level pathogenic Pseudomonas aeruginosa infection
US20150284450A1 (en) Combination therapies using anti-pseudomonas psl and pcrv binding molecules
BR112013031485B1 (pt) Anticorpo monoclonal isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, usos e método in vitro para bloqueio ou prevenção da ligação de p. aeruginosa a células epiteliais
JP2012516897A (ja) シュードモナス・エルギノーサ（ＰｓｅｕｄｏｍｏｎａｓＡｅｒｕｇｉｎｏｓａ）感染の治療のための抗生物質と抗体療法との組み合わせ
HK1201453B (en) Combination therapies using anti- pseudomonas psl and pcrv binding molecules
NZ722379B2 (en) Combination therapies using anti-pseudomonas psl and pcrv binding molecules

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140714

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141016

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150304